Insitro

The AI engine Fit Assessment

Beta

Insitro effectively utilizes machine learning to discover patterns and expand therapeutics, optimizing the drug discovery process.

Blurb

Insitro is a drug discovery and development startup that utilizes machine learning and biology to transform drug discovery.

HQ Location

South San Francisco (United States)

Founded

2018

Employees

201 - 500

Total funding raised

$643.00M

Funding Status

Series C, $400.00M, March 15, 2021
Subspaces
  • Drug Repurposing
  • Drug Discovery Optimization

insitro is the physical AI company unlocking causal human biology, founded and led by AI pioneer Daphne Koller. By generating the world’s largest integrated multi-modal corpus of human and cellular data, we’ve built the Virtual Human™ – a genetically anchored causal AI engine that reveals how disease begins, progresses, and can be resolved. Our platform enables us to precisely identify causal genetic drivers and deploy our TherML™ AI platform to design optimal medicines, advancing a broad pipeline of therapeutics for neuroscience and metabolic diseases. This industrialized architecture creates a self-learning loop: with every biology we onboard, our predictive models grow smarter, accelerating discovery across scales of biology.



Join us in transforming the future of medicine!